Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors

Commentary on: 1. Holman RR, 2. Haffner SM, 3. McMurray JJ, 4. et al .; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463–76. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] The aim of the NAVIGATOR study was to determine whether the risk of diabetes and cardiovascular events could be reduced in people with impaired glucose tolerance using nateglinide in addition to a lifestyle modification programme. Nine thousand three hundred and six adults with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors were enrolled in this study and randomly assigned, with the use of an interactive voice-response telephone system, to nateglinide at a dose of 60 mg three times daily or placebo in addition to participation in a lifestyle modification programme. Both the participants and the investigators were unaware of the treatment assignments. Participants returned … [1]: {openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.issn%253D0028-4793%26rft.volume%253D362%26rft.issue%253D16%26rft.spage%253D1463%26rft.epage%253D1476%26rft.atitle%253DEffect%2Bof%2Bnateglinide%2Bon%2Bthe%2Bincidence%2Bof%2Bdiabetes%2Band%2Bcardiovascular%2Bevents.%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa1001122%26rft_id%253Dinfo%253Apmid%252F20228402%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1056/NEJMoa1001122&link_type=DOI [3]: /lookup/external-ref?access_num=20228402&link_type=MED&atom=%2Febmed%2F16%2F1%2F7.atom [4]: /lookup/external-ref?access_num=000276894700006&link_type=ISI